Estudo dos fatores genéticos de risco para o infarto agudo do miocárdio em idade precoce

O mecanismo patogênico mais importante no IAM é a oclusão trombótica de uma artéria coronariária no local de ruptura de uma placa aterosclerótica. Recentemente, diversos estudos têm investigado a associação entre o IAM e fatores genéticos protrombóticos. O presentetrabalho é um estudo tipo caso-controle a fim de avaliar o efeito de diversos polimorfismos genéticos em um grupo de pacientes com IAM antes dos 60 anos de idade. Foram investigados 283 pacientes e 93 indivíduos controles, todos caucasóides e sem diferenças quanto à proporção sexual e idade média entre os grupos.The most important mechanism of AMI is the thrombotic oclusion of coronary artery at the site of a ruptured atherosclerotic plaque. Recently, several studies have been investigated the association between the AMI risk and prothrombotic genetic factors. The present study is a case-control study to evaluate the effect of several genetic polymorphisms in a case group with AMI before the age of 60 years. 283 patients and 93 control subjects were investigated, all caucasian and without sex and age differences between groups

Estudo dos fatores genéticos de risco para o infarto agudo do miocárdio em idade precoce

O mecanismo patogênico mais importante no IAM é a oclusão trombótica de uma artéria coronariária no local de ruptura de uma placa aterosclerótica. Recentemente, diversos estudos têm investigado a associação entre o IAM e fatores genéticos protrombóticos. O presentetrabalho é um estudo tipo caso-controle a fim de avaliar o efeito de diversos polimorfismos genéticos em um grupo de pacientes com IAM antes dos 60 anos de idade. Foram investigados 283 pacientes e 93 indivíduos controles, todos caucasóides e sem diferenças quanto à proporção sexual e idade média entre os grupos.The most important mechanism of AMI is the thrombotic oclusion of coronary artery at the site of a ruptured atherosclerotic plaque. Recently, several studies have been investigated the association between the AMI risk and prothrombotic genetic factors. The present study is a case-control study to evaluate the effect of several genetic polymorphisms in a case group with AMI before the age of 60 years. 283 patients and 93 control subjects were investigated, all caucasian and without sex and age differences between groups

Está o polimorfismo da metilenotetrahidrofolato redutase (G677-A) associado com a doença coronariana?

25

Estudo do polimorfismo -1185A/G da região promotora do gene do fator Von Willebrand (FVW) e níveis plasmáticos do FVW:Ag na doença coronariana

28

Estudo do polimorfismo -1185A/G da região promotora do gene do fator Von Willebrand (FVW) e níveis plasmáticos do FVW:Ag na doença coronariana

28

Matrix metalloproteinase gene polymorphisms in patients with coronary artery disease

Matrix metalloproteinases (MMPs) play an important role in the pathogenesis of atherosclerosis, the pathology underlying the majority of coronary artery disease (CAD). In this study we tested the hypothesis that polymorphic variation in the MMP genes influences the risk of developing atherosclerosis. We analyzed functional polymorphisms in the promoter of the MMP-1, MMP-3, MMP-9 and MMP-12 genes in 183 Brazilian Caucasian individuals submitted to coronary angiography, of which 67 (37%) had normal coronary arteries (control group) and 116 (63%) had CAD (CAD patient group). The -1607 1G/2G MMP-1, -1171 5A/6A MMP-3, -1562 C/T MMP-9, -82 A/G MMP-12 polymorphisms were analyzed by PCR followed by restriction digestion. No significant differences were observed in allele frequencies between the CAD patients and controls. Haplotype analysis showed no differences between the CAD patients and controls. There was a significant difference in the severity of CAD, as assessed by the number of diseased vessels, in MMP-1 1G/1G homozygous individuals and in those homozygous for the 6A allele of the MMP-3 polymorphism. However, multivariate analysis showed that diabetes mellitus was the only variable independently associated with CAD severity. Our findings indicated that MMP polymorphisms have no significant impact on the risk and severity of CAD

Association studies between -1185A/G von Willebrand factor gene polymorphism and coronary artery disease

High levels of von Willebrand factor (vWF) have been associated with cardiovascular disease. The A allele of the -1185A/G polymorphism in the 5'-regulatory region of the vWF gene was associated with the highest plasma vWF levels in a normal population. To examine the association between -1185A/G polymorphism and coronary artery disease (CAD), 173 Brazilian Caucasian subjects submitted to coronary angiography were studied. Of these, 57 (33%) had normal coronary arteries (control group) and 116 (67%) had CAD (patient group). Plasma vWF levels were higher in patients (145 U/dl) than in controls (130 U/dl), but the differences were significant only for O blood group subjects. Polymerase chain reaction amplification of the 864-bp vWF promoter region followed by AccII restriction digestion was used to identify the -1185A/G genotypes. The -1185A allele frequency was 43.1% in patients and 44.7% in controls. Allele and genotype frequencies were not significantly different between patients and controls. No association was observed between the -1185A/G genotypes and plasma vWF levels in patients or controls. These results suggest that -1185A/G polymorphism is not an independent risk factor for CAD

Matrix metalloproteinase gene polymorphisms in patients with coronary artery disease

Abstract Matrix metalloproteinases (MMPs) play an important role in the pathogenesis of atherosclerosis, the pathology underlying the majority of coronary artery disease (CAD). In this study we tested the hypothesis that polymorphic variation in the MMP genes influences the risk of developing atherosclerosis. We analyzed functional polymorphisms in the promoter of the MMP-1, MMP-3, MMP-9 and MMP-12 genes in 183 Brazilian Caucasian individuals submitted to coronary angiography, of which 67 (37%) had normal coronary arteries (control group) and 116 (63%) had CAD (CAD patient group). The -1607 1G/2G MMP-1, -1171 5A/6A MMP-3, -1562 C/T MMP-9, -82 A/G MMP-12 polymorphisms were analyzed by PCR followed by restriction digestion. No significant differences were observed in allele frequencies between the CAD patients and controls. Haplotype analysis showed no differences between the CAD patients and controls. There was a significant difference in the severity of CAD, as assessed by the number of diseased vessels, in MMP-1 1G/1G homozygous individuals and in those homozygous for the 6A allele of the MMP-3 polymorphism. However, multivariate analysis showed that diabetes mellitus was the only variable independently associated with CAD severity. Our findings indicated that MMP polymorphisms have no significant impact on the risk and severity of CAD